AstraZeneca Plc’s Lynparza gets US FDA approval

  • Dec 30, 2019 GMT
  • Team Kalkine
  AstraZeneca Plc (LON: AZN) has informed about the approval of Lynparza for pancreatic cancer by US FDA.
  • The company has informed that the medicine has been approved in the US as a First-line maintenance therapy.
  • Based on an FDA-approved companion diagnostic for the drug Lynparza, patients will be selected for therapy.
  • The approval follows a recommendation from the ODAC (Oncologic Drugs Advisory Committee) and was based on results from the pivotal Phase III POLO trial, which was presented at the 2019 American Society of Clinical Oncology Annual Meeting and had been published in The New England Journal of Medicine.
  • On 30th December 2019, at the time of writing, GMT 14:30 PM, AZN shares were trading at GBX 7,730.00, down by15 points against the previous day closing price.

With Bank of England reducing the interest rates to a historic low level, the spotlight is back on diverse investment opportunities. 

Amidst this, are you getting worried about these falling interest rates and wondering where to put your money?

Well! Team Kalkine has a solution for you. You still can earn a relatively stable income by putting money in the dividend-paying stocks.

We think it is the perfect time when you should start accumulating selective dividend stocks to beat the low-interest rates, while we provide a tailored offering in view of valuable stock opportunities and any dividend cut backs to be considered amid scenarios including a prolonged market meltdown.

To know more about these dividend stocks, click here

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK